Table 2.
Spearman correlation analysis of glucose metabolism parameters, general condition, anthropometric parameters, biochemical, immunological and virological indicators within 156 wk (n = 61)
|
|
FPG
|
FINS
|
HOMA-IR
|
HOMA-β
|
||||
|
r
|
P
value
|
r
|
P
value
|
r
|
P
value
|
r
|
P
value
|
|
| Age (yr) | 0.120 | 0.008 | ||||||
| NAFLD (0 = without, 1 = with) | 0.155 | 0.001 | ||||||
| Follow-up weeks | 0.280 | 0.005 | ||||||
| BMI (kg/m2) | 0.291 | 0.004 | ||||||
| Body fat percentage (%) | 0.311 | 0.002 | ||||||
| Body fat weight (kg) | 0.297 | 0.003 | ||||||
| Lean body mass weight (kg) | 0.138 | 0.008 | ||||||
| ALT (g/L) | 0.126 | 0.006 | 0.221 | 0.031 | ||||
| AST (g/L) | 0.081 | 0.029 | 0.352 | < 0.0001 | ||||
| GGT (g/L) | 0.127 | 0.005 | 0.230 | 0.025 | ||||
| ALP (g/L) | 0.106 | 0.004 | 0.253 | 0.009 | 0.164 | 0.002 | ||
| Cr (μmol/L) | 0.198 | < 0.0001 | 0.378 | 0.027 | ||||
| Cysc (mg/L) | -0.280 | 0.005 | ||||||
| UA (mmol/L) | 0.175 | 0.001 | 0.179 | < 0.0001 | ||||
| CD3+ count (cells/μL) | -0.146 | < 0.0001 | ||||||
| CD4+count (cells/μL) | -0.107 | 0.030 | ||||||
| CD8+count (cells/μL) | -0.120 | 0.002 | -0.236 | 0.022 | -0.121 | 0.026 | ||
| CD3+% | -0.140 | 0.002 | ||||||
| CD4+% | 0.2363 | 0.023 | 0.111 | 0.042 | 0.118 | 0.030 | ||
| CD8+% | 0.134 | 0.007 | -0.293 | 0.004 | ||||
| CD4+/CD8+ | 0.312 | 0.002 | ||||||
| IgM (g/L) | -0.263 | 0.003 | ||||||
| LV (copes/L) | -0.266 | 0.033 | -0.374 | 0.045 | -0.427 | 0.024 | ||
| CD4+ count groups | -0.340 | 0.049 | ||||||
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; Cr: Serum creatinine; Cysc: Serum cystatin C; FINS: Fasting insulin; FPG: Fasting plasma glucose; GGT: γ-Glutamyl transpeptidase; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; IgM: Immunoglobulin M; NAFLD: Nonalcoholic fatty liver disease; UA: Uric acid; VL: Viral load.